Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stea, S.
Right arrow Articles by Bolton, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stea, S.
Right arrow Articles by Bolton, W. K.

Journal of the American Society of Nephrology, Vol 7, 2399-2402, Copyright © 1996 by American Society of Nephrology

REGULAR ARTICLES

Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis

S Stea, T Bachelor, M Cooper, P de Souza, K Koenig and WK Bolton
Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville 22908, USA.

This study investigated the disposition and bioavailability of ceftazidime when it was given intraperitoneally. Seven patients were given 1 gm of ceftazidime intravenously, and 1 wk later, the same dose was given intraperitoneally. After both intravenous and intraperitoneal dosing, serum and peritoneal dialysate samples were obtained at set time intervals over a 24-h period. High-performance liquid chromatography was used to determine the ceftazidime concentrations in the serum and dialysate samples. Inspection of the concentration versus time data after intraperitoneal dosing demonstrated that serum ceftazidime concentrations reached therapeutic (> 8 micrograms/mL) levels within 30 min and remained in the therapeutic range for the entire 24-h period. Simulation of a variety of ceftazidime dosing regimens using the mean pharmacokinetic parameters from this population of patients suggests that a regimen of 1.5 gm administered intraperitoneally every 24 h produces trough serum drug concentrations (approximately 40 micrograms/mL) similar to those achieved with a standard regimen of 1.0 gm given intravenously every 24 h in patients undergoing continuous ambulatory peritoneal dialysis. It was concluded that the intraperitoneal dosing of ceftazidime in these patients is an equally effective and a more convenient alternative to its administration.


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
W. Van Biesen, N. Veys, R. Vanholder, and N. Lameire
Peritoneal-dialysis-related peritonitis: the art of rope-dancing
Nephrol. Dial. Transplant., November 1, 2002; 17(11): 1878 - 1882.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. SCHAEFER, G. KLAUS, D. E. MÜLLER-WIEFEL, and O. MEHLS
Intermittent versus Continuous Intraperitoneal Glycopeptide/Ceftazidime Treatment in Children with Peritoneal Dialysis-Associated Peritonitis
J. Am. Soc. Nephrol., January 1, 1999; 10(1): 136 - 145.
[Abstract] [Full Text]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673